University Of Strathclyde

Tenax Therapeutics Appoints Gillian Andor as VP of Clinical Operations to Bolster Phase 3 Program

4 months ago

• Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103). • Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study. • Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). • The appointment signifies Tenax's commitment to strengthening its clinical development capabilities as it prepares for potential global regulatory filings.

Strategic Approaches to Securing Market Access for Orphan Drugs: Beyond HTA Approval

8 years ago

• Clinician engagement and education are crucial for orphan drug adoption, requiring targeted materials that effectively communicate disease burden and clinical benefits. • Real-world evidence collection through independent registries plays a vital role in demonstrating orphan drug effectiveness, despite manufacturer funding challenges. • Patient support networks, including home nurse visits and online platforms, can enhance treatment outcomes while helping justify high orphan drug costs to payers.